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RELAPSING-REMITTING MULTIPLE SCLEROSIS: ADVANCES IN DISEASE-
MODIFYING THERAPIES 
KATHLEEN KAY 
ABSTRACT 
Multiple sclerosis is a demyelinating disease affecting the central nervous system. It is 
the most prevalent disabling neurological condition among young adults, with onset 
typically between 20 and 40 years of age. Infiltrating immune cells and microglia 
activations are associated with inflammatory and neurodegenerative mechanisms. Current 
available disease modifying therapies suppress or modulate the immune system. These 
pharmaceuticals differ with respect to administration route and frequency, adverse 
effects, and efficacy. This paper provides a thorough manuscript illustrating the major 
prescribing factors, efficacy profiles, adverse events, and contraindications that patients 
and clinicians should consider while choosing a treatment. Despite the advancements 
made over the past 20 years, patients with progressive multiple sclerosis have few 
therapeutic options. Additionally, this paper assesses emerging therapies and disease 
targets on the pharmaceutical horizon, which have shown promise for all disease 
phenotypes. 
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I. Introduction 	  
Multiple sclerosis (MS) is a heterogeneous inflammatory disease characterized by 
plaque formation and the demyelination of the central nervous system (CNS) (Mallucci et 
al., 2015). Those afflicted experience varying degrees of sensory, motor, and cognitive 
deficits. According to the National Multiple Sclerosis Society, it is estimated that 400,000 
individuals in the United States and 2.3 million individuals worldwide suffer from MS 
(“MS Prevalence,” n.d.). Believed to be influenced by both genes and the environment, 
disease onset generally occurs between 20 and 40 years of age, and women have a higher 
disease prevalence (Kalman and Lublin, 1999). Data suggest that there is a greater 
prevalence of MS further from the equator, although certain ethnic populations have 
significantly lower incidences of the disease in spite of their residential latitude (Kalman 
and Lublin, 1999). Other potential triggers include viral and bacterial infections (Agrawal 
and Yong, 2007). The etiology and pathogenesis of MS remains a conundrum, despite 
extensive research.  
 
Diagnosic criteria 
No single definitive test exists for the diagnosis of MS. This diagnosis rests upon 
clinical evaluation and diagnostic tests utilized to rule out other conditions. Classification 
of MS is dependent on disease activity and progression (Mallucci et al., 2015). Clinical 
manifestations of disease activity may be too subtle to detect, but closely monitoring 
cognitive, visual, and other changes helps to identify it (Lublin et al., 2014). Magnetic 
resonance imaging (MRI) is the most sensitive diagnostic tool and plays an essential role 
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in the detection of pathological alterations of the central nervous system (CNS). As stated 
by Radue et al. (2010): 
“Magnetic resonance imaging (MRI) may be used to observe the 
course of multiple sclerosis (MS) by revealing active inflammation and 
migration of lymphocytes across the blood-brain barrier (appearing as T1 
gadolinium-enhancing [Gd+] lesions), overall disease burden (total T2-
hyperintense lesion load), and irreversible central nervous system (CNS) 
damage (indicated by chronic, persistent T1-hypointense lesions and brain 
volume loss).” 
In addition to MRI measures of disease activity, cerebrospinal fluid (CSF) may be 
analyzed for abnormalities. However, CFS biological markers do not reliably 
differentiate between MS disease phenotypes. The CSF usually contains elevated 
levels of antibodies, oligoclonal bands, and certain proteins associated with the 
breakdown of myelin (Haines et al., 2015). 
Lublin et al. (2014) classifies the disease course by one of three clinical 
presentations, clinical isolated syndrome (CIS), relapsing-remitting multiple sclerosis 
(RRMS), or progressive multiple sclerosis, subdivided into primary and secondary 
categories (Table 1). Although not initially included as a clinical descriptor, CIS is as an 
early presentation of MS that falls short of the clinical diagnosis (Mallucci et al., 2015). 
CIS is characterized as an “acute or sub acute onset of monophasic episode suggestive of 
Multiple Sclerosis” (Mallucci et al., 2015, p. 2). While CIS fails to fulfill MS diagnostic 
criteria, Lublin et al. (2014) reports that 30% to 70% of patients develop MS, with 
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prevalence varying with location of CIS episode. Accounting for approximately 85% of 
all MS cases, relapsing-remitting multiple sclerosis (RRMS) fluctuates between periods 
of symptomatic relapse and complete or partial remission of neurological dysfunction 
(Lublin et al., 2014). RRMS affects women more frequently than men (Lublin et al., 
2014). Lublin et al. (2014) subcategorizes progressive MS into secondary progressive and 
primary progressive MS. Seventy-five percent of RRMS cases transition to secondary 
progressive multiple sclerosis (SPMS) within 15 years of onset. It is characterized by a 
progressive deterioration in neurological function post relapsing phase (Lublin et al., 
2014). Primary progressive multiple sclerosis (PPMS) lacks the acute relapsing course of 
the disease and, therefore, experiences a steady increase in neurological deficits from the 
initial onset (Lublin et al., 2014). This progression is assessed yearly by clinical and 
imaging criteria. 
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Table 1. Characteristics of MS Phenotypes. Adapted from Mallucci et al., 2015. 
Clinical Form Disease Course 
Clinical isolated syndrome (CIS) Characterized by acute or sub acute onset of 
monophasic episode suggestive of MS, that has yet to 
meet the diagnostic criteria. The episode lasts more 
than 24h and usually affects optic nerve, brain stem or 
spinal cord. 
Between 30% and 70% patients with CIS develop MS: 
In patients with optic neuritis CIS conversion to MS 
varies between 10% and 85%. 
In patients with brainstem syndrome CIS conversion 
to MS varies between 50% and 60%. 
In patients with spinal cord CIS conversion to MS 
varies between 40% and 60%. 
Age of onset between 20 and 45 years 
Female to male ratio between 2:1 and 5:1. 
 
Relapsing-remitting MS (RR MS) Characterized by relapses over days to weeks, 
followed by complete or partial remissions over 
months or years 
~85% of cases: 
Age of onset between 20 and 30 years 
Female to male ratio between 2:1 and 3:1 
Progressive MS 
   Secondary Progressive MS (SP 
MS) 
    
 
 
    
   Primary Progressive MS (PP MS)  
 
Characterized by progressive accumulation of 
disability after initial relapsing course of the disease. 
~75% of RR MS cases within 15 years of the initial 
diagnosis 
 
 
Characterized by steady functional worsening from the 
onset of the disease 
~15% of cases: 
Later onset than RR MS (by ~10 years) 
Female to male ratio: 1:1 
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Neuropathology 
MS is characterized by axonal demyelination and damage as well as neuronal 
damage associated with the infiltration of immune cells and microglia activation. Chronic 
inflammation of the CNS leads to the formation of lesions in the white matter and cortical 
and subcortical grey matter (Lassmann, 2013). Neuronal degeneration and plaque 
formation varies between patients, as well as between plaques within a patient. Astrocyte 
function is also affected. Their disturbance may induce an immune response or may alter 
the vulnerability of oligodendrocytes or neurons (Brosnan and Raine, 2013). Within 
active lesions, disruption of perivascular and subpial glia limitans results in the loss of 
astrocyte polarity (Brosnan and Raine, 2013). Astrocytes form glial scars (Brosnan and 
Raine, 2013). 
Early active plaques are heterogeneous and are characterized by extensive 
immune cell infiltration (Pierson et al., 2012). “The different lesion types can be 
delineated on the basis of specific myelin protein loss, presence or absence of infiltrating 
T cells and macrophages, the accumulation of immunoglobulin and complement 
(signaling a role of pathogenic autoantibodies), and the presence or absence of severe 
oligodendrocyte degeneration” (Pierson et al., 2012, p. 206). The majority of lesions are 
located in the periventricular white matter, cerebellum, brain stem, and optic nerves 
(Pierson et al., 2012). Patients may also have spinal cord lesions (Pierson et al., 2012). 
Based on pathological studies as well as some radiology studies, spinal cord lesions are 
mainly present in SPMS and PPMS patients (Nociti et al., 2005). 
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Oligodendrocytes produce insulating myelin sheaths around axons of the CNS, 
which allows saltatory nerve conduction  (Bradl and Lassmann, 2010). In the event of 
myelin or oligodendrocyte damage, axonal support and insulation is compromised and 
deficits in neuronal function ensue (Mallucci et al., 2015). MS is profoundly 
heterogeneous. Identifying the mechanisms involved in its pathogenesis is of great 
importance to the development of effective therapies. Inferences about disease 
mechanisms are often made through the utilization of an animal model of MS, 
experimental autoimmune encephalomyelitis (EAE) (Agrawal and Yong, 2007). 
Although the etiology and pathogenesis have yet to be elucidated, current theories 
suggest that MS is an autoimmune inflammatory disorder, with infiltrating T cells and 
activated microglia causing degeneration and demyelination. 
T cells are necessary for fighting infectious pathogens, but an inappropriate 
response is to blame in many autoimmune diseases. Known to regulate the development 
and function of T-helper (Th) cells and oligodendrocytes, the Notch signaling pathway is 
the foundation of cell-to-cell communication (Bassil et al., 2013). The Notch signaling 
pathway is comprised of Notch 1, 2, 3, and 4 transmembrane receptors and their Delta-
like 1, 3, and 4 and Jagged 1 and 2 ligands (Bassil et al., 2013). These ligands induce 
proteolytic cleavage of the receptor, releasing the Notch intracellular domain (NICD) 
(Bassil et al., 2013). NICD translocates to the nucleus and initiates transcription (Figure 
1). Delta-like ligands promote Th1 cell differentiation, while Jagged ligands promote Th2 
cells (Bassil et al., 2013). Studies suggest that Th1 and Th17 cells are mainly pathogenic 
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in human and animal models of MS, while Th2 and regulatory T (Treg) cells are anti-
inflammatory (Bassil et al., 2013) (Figure 2).	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Figure	  1.	  Diagram	  of	  Notch	  signaling	  pathway.	  	  
Source:	  Bassil	  et	  al.,	  2014	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Figure	  2.	  Illustration	  of	  CD4+	  T	  cell	  Differentiation	  Based	  of	  the	  cytokine	  milieu	  and	  transcription	  factors	  (below	  the	  arrows),	  naïve	  CD4+	  T	  cell	  can	  differentiate	  into	  various	  Th	  cells.	  Adapted	  from	  Bassil	  et	  al.,	  2013.	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The CNS stringently regulates the trafficking of immune cells, enabling only 
limited access (Engelhardt and Ransohoff, 2012). Immune cells extravasate from the 
vasculature into the CNS via interaction between adhesion molecules and their ligands 
(Engelhardt and Ransohoff, 2012). Leukocytes express surface α4 integrins that interact 
with their endothelial-expressed ligands: vascular cell adhesion molecule (VCAM)-1 and 
mucosal addressin cell adhesion molecule (MAdCAM)-1 (Engelhardt and Ransohoff, 
2012). This interaction slows the leukocytes and enables diapedesis across the blood-
brain barrier. The invasion of autoaggressive cells triggers inflammatory events that 
recruit additional immune cells, exacerbating the inflammation and damage to the CNS 
(Engelhardt and Ransohoff, 2012). 
Although the mechanisms involved in brain inflammation and immune-mediated 
tissue injury have not been fully elucidated, it is widely accepted that inflammation is 
associated with active peripheral T cells that recognize specific CNS molecules. 
Normally, microglia and dendritic cells, antigen presenting cells (APCs), recognize 
pathogen-associated molecular patterns, which generate proinflammatory signals to 
protect against invading pathogens (Agrawal and Young, 2007). If APCs become reactive 
against endogenous proteins, they stimulate the production of self-reactive T cells, 
characteristic of many neurodegenerative diseases (Figure 3). 
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Figure 3. Immune response in MS. This is a hypothetical view of the immune response 
in acute multiple sclerosis lesions. Proinflammatory cytokines and antigens induce an 
immune response in the CNS. T and B cells readied in the peripheral lymphoid tissue, 
then migrate into the CNS. Microglia and CD4+ T cells produce more inflammatory 
cytokines, and these cytokines attract other immune cells. 
Source: Hemmer et al., 2002 
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CD4+ and CD8+ T cells play major roles in the immune response. Additionally, an 
increase in immunoglobulins (Igs) detected in the CSF suggests that both B cells and Igs 
have a hand in MS pathogenesis (Agrawal and Yong, 2007). Under normal 
circumstances, B cells are unable to cross the blood-brain barrier; however inflammation 
causes it to be “leaky” (Agrawal and Yong, 2007). B cells can act as APCs and recruit T 
lymphocytes to the parenchyma, and they can secrete myelin-specific antibodies causing 
tissue damage (Agrawal and Yong, 2007). CD8+ T cell infiltrates are the major 
constituents of MS lesions (Skulina et al., 2004). A positive correlation exists between 
axonal damage and the number of CD8+ T cell infiltrates, as well as MRI measures of 
disease and CD8+ T cells detectable in blood (Skulina et al., 2004).  
CD4+ T cells play an equally crucial role in pathogenesis. According to a study 
performed by Tzartos et al. (2008), T cells, astrocytes, and oligodendrocytes increased 
the expression of interleukin (IL)-17 in areas of inflammation and active demyelinating 
lesions. Within acute lesions and along the active borders of chronically active ones, 
significantly greater densities of both CD4+ IL-17+ and CD8+ IL-17+ T cells were 
observed (Tzartos et al., 2008). Observed by Zhang et al. (2015), the production of IL-11, 
along with IL-17, was significantly increased in T lymphocytes in RRMS, suggesting that 
it too plays a role in the proinflammatory response. Demonstrated in this study, Th17 
cytokines IL-17F, IL-21, and tumor necrosis factor α (TNF-α), and transforming growth 
factor β1 (TGF-β1) induced the differentiation of IL-11+CD4+ T cells. IL-17F, TNF-α, 
TGF-β1, IL-1β promoted the secretion of IL-11 from CD4+ T cells (Zhang et al., 2015).  
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TNF-α-induced IκB phosphorylation activates the nuclear factor (NF)-κB 
pathway, which upregulates the expression of proinflammatory chemokines, such as 
monocyte chemotactic protein-1 (MCP-1), and adhesion molecules, including VCAM-1 
and E-selectin (Wei et al., 2015). All of these molecules are necessary for the attraction, 
adhesion, and diapedesis of white blood cells out of the vasculature. Cyclooxygenase-2 
(COX-2) and nitric oxide synthase (iNOS), major components of the inflammatory 
response, are likewise target genes of the NF-κB pathway (Wei et al., 2015).  
Furthermore, a reduction of molecules involved in water homeostasis, glutamate 
buffering, and energy coupling with oligodendrocytes may exacerbate demyelination and 
neuronal damage (Lassmann, 2013). In order to produce the necessary proteins required 
for myelination, oligodendrocytes have an extremely high metabolic rate. An unavoidable 
by-product of cellular respiration, excess reactive oxygen and nitric oxide species may 
lead to detrimental mitochondrial injury. Activated macrophages also produce nitric 
oxide and glutamic acid (Bruck, 2005). Excessive nitric oxide exposure causes a 
conduction block in demyelinated axons, axonal degeneration, and damage to axonal 
membranes, which may cause ruptures (Bruck, 2005). Axonal damage occurs early in 
lesion formation and mainly in areas of acute inflammation and demyelination  (Bruck, 
2005; Ferguson et al., 1997). 
 
Disease-­‐modifying	  therapies 
Currently, the main objective of MS disease-modifying therapies (DMTs) is to 
retard the progression of neurodegeneration by modulating or suppressing the 
autoimmune response. The approved, available DMTs have only elicited proven 
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beneficial results in RRMS patients (Wingerchuk and Carter, 2014). With few options for 
the progressive phenotypes, current research efforts are directed towards compounds with 
regenerative and neuroprotective properties. These immunomodulatory and 
immunosuppressant drugs can partially ameliorate disease outcome, but they are in no 
way a cure and are associated with a plethora of side effects and risks. Patients and their 
clinicians must weigh the costs and benefits of each treatment option and decide on the 
one most suited to the patient’s lifestyle. 
 
Goals 
Unfortunately, no single pathogenetic mechanism has been identified that would 
enable the development of a universal therapeutic approach. Studies suggest the MS has a 
multifactorial etiology. In addition, MS is highly heterogeneous within and between 
patients, not only in pathogenesis, but also in response to DMTs. This further complicates 
the treatment process. With considerable published research relating to the safety and 
efficacy of MS pharmaceuticals and several drugs in various stages of clinical trials, a 
comprehensive analysis would benefit patients and clinicians alike. The objective of this 
paper is to provide the reader with a comprehensive manuscript that emphasizes safety, 
efficacy, and major prescribing factors patients and clinicians should consider while 
devising a personalized treatment plan. The hope is that they will have a greater 
understanding of the complex mechanisms that contribute to MS pathogenesis as well as 
the need for individually tailored approaches for disease management.  
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II. Clinical Effectiveness of MS Disease Modifying Therapeutics 
 Approved	  in	  the	  early	  to	  mid	  90s,	  self-­‐injectable	  DMTs	  were	  the	  first	  available	  therapies	  used	  for	  the	  treatment	  of	  RRMS	  (Wingerchuk	  and	  Carter,	  2014),	  and	  even	  with	  the	  recent	  introduction	  of	  oral	  medications,	  these	  injectable	  DMTs	  typically	  serve	  as	  the	  primary	  treatment	  for	  RRMS	  (Sedal	  et	  al.,	  2014).	  Due	  to	  this	  twenty-­‐year	  period	  of	  usage,	  the	  adverse	  event	  profiles	  and	  efficacy	  and	  safety	  profiles	  are	  well	  documented,	  which	  provides	  patients	  and	  clinicians	  with	  a	  comprehensive	  therapeutic	  representation	  that	  the	  newer	  medications	  lack	  (Sedal	  et	  al.,	  2014).	  Interferon beta (IFNβ) and glatiramer acetate (GA) are widely utilized as	  first-­‐line	  therapies	  for the management of RRMS,	  but	  they	  have	  relatively	  low	  adherence	  rates	  and	  moderate	  efficacy. Although commonly prescribed, other 
therapies have been proven more efficacious for curbing clinical and MRI measures of 
disease progression. The following studies outline the mechanisms of action, 
effectiveness, safety, and contraindications of the Food and Drug Administration (FDA) 
approved RRMS medications. Available treatments, their dosing regimes, monitoring 
suggestions, and adverse events are listed below (Table 2).  	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Table 2. Current available medications for relapsing-remitting multiple sclerosis. 
Factors to consider when choosing a therapeutic strategy. Full blood count (FBC), liver 
function tests (LFT), subcutaneous (s.c.), intramuscular (i.m.). Adapted from Sedal et al., 
2014. 
 Dosing Frequency of 
dosing 
Adverse 
effects 
Monitoring 
Injectable 
medications 
    
IFNβ-1b 
 
IFNβ-1a 
IFNβ-1a 
IFNβ-1a 
 
250 µg 
 
30 µg 
22-44 µg 
125 µg 
Every other 
day, s.c. 
Weekly, i.m. 
3x/week, s.c. 
Every 2 weeks, 
s.c. 
 
Injection site reactions, flu-
like symptoms, leukopenia, 
elevated liver enzymes, 
thyroid dysfunction, platelet 
reduction, tolerance 
FBC and LFT at 
baseline, 1,3, and 6 
months then yearly 
Glatiramer acetate 20 mg 
40 mg 
Daily, s.c. 
3x/week, s.c. 
Injection site reactions, 
transient systemic post-
injection reactions 
FBC and LFT at 
baseline and 1 month 
then yearly 
Intravenous 
medications 
    
Natalizumab 300 mg Every 4 weeks Allergic reactions, fatigue, 
liver toxicity, headache, 
fatigue, PML 
JCV testing (every 3-6 
months if negative), 
MRI at baseline then 
yearly (3-6 months if 
JCV positive) 
FBC and LFT at 
baseline, 3 months and 
then biannually 
Oral medications     
Fingolimod 0.5 mg Daily Bradycardia and conduction 
block during initiation, 
elevated liver enzymes, risk 
of herpes infections, 
macular edema, PML (rare) 
Cardiac monitoring at 
initiation 
Eye examination at 
baseline and 3-6 
months 
FBC and LFT at 
baseline, 1 month, and 
then every 4 months 
 
Dimethyl fumarate 
BG12 
240 mg Twice daily Flushing, gastrointestinal 
events, PML (rare) 
FBC and urine protein 
at baseline, 1 month 
then 6-12 months 
 
Teriflunomide 7-14 mg Daily Diarrhea, nausea, headache, 
nasopharyngitis, fatigue, 
alopecia, elevated alanine 
aminotransferase levels, 
pain in arms, legs, and back, 
and PML (rare) 
 
FBC and LFT monthly 
for 6 months then 
every 6-8 weeks 
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Interferon beta 
 Four preparations of IFNβ have been approved for the treatment of RRMS 
(Mallucci et al., 2015; “Plegridy,” n.d.). A 250 µg dose of subcutaneous IFNβ-1b is 
administered every other day, while subcutaneous IFNβ-1a 22 µg or 44 µg is 
administered three times a week, subcutaneous	  IFNβ-1a 125 µg every	  2	  weeks,	  and	  
intramuscular IFNβ-1a 30 µg, weekly (Mallucci et al., 2015; “Plegridy,” n.d.).  
Interferons are naturally occurring anti-inflammatory cytokines (Kieseier, 2011). 
Although the mechanism is incompletely understood, IFNβ upregulates the anti-
inflammatory cytokine expression and downregulates the pro-inflammatory cytokine 
expression (Kieseier, 2011). A study by Chen et al. (2009) suggests that, in addition to 
the modulation of Th1 and Th2 groups, IFNβ has the ability to inhibit the production of 
osteopontin (OPN), a mediator of leukocyte activation and cytokine production, and IL-
17 in CD4+ T cells.   
 In a double-blind placebo controlled study, subcutaneous IFNβ-1a was 
investigated for its safety and efficacy in the treatment of RRMS (Ebers, 1998). The 
PRISMS study illustrated that subcutaneous IFNβ-1a reduced disease exacerbations and 
delayed disability progression over the two-year trial course (Ebers, 1998). Compared to 
the placebo, IFNβ-1a 22 µg and 44 µg significantly reduced the number of relapses per 
patient during the 2-year trial period by 27% and 33%, respectively (Ebers, 1998). A 
reduction in the number of moderate and severe relapses was also greatly reduced with 
IFNβ-1a treatment (Ebers, 1998). Significant reductions in Expanded Disability Status 
Scale (EDSS) and increases in sustained progression were observed in both IFNβ-1a 
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groups (Ebers, 1998). Compared to the placebo group, patients in the low-dose IFNβ-1a 
group had 67% fewer T2 hyperintense lesions, while the high-dose IFNβ-1a group had 
78% fewer lesions (Ebers, 1998). 
Headache, influenza-like symptoms, generally mild injection-site reactions, 
fatigue, myalgia, and fever were the most common adverse events (Ebers, 1998). 
Asymptomatic decreases in white blood cells, neutrophils, and lymphocytes, and slightly 
elevated liver enzyme levels were observed (Ebers, 1998).  
 
Glatiramer acetate 
Twenty milligrams of subcutaneous glatiramer acetate (GA) administered daily is 
indicated for the treatment of RRMS (Mallucci et al., 2015).  It is a random polymer 
composed of glutamic acid, lysine, alanine, and tyrosine, which are found in myelin basic 
protein (Mallucci et al., 2015). As of January 2014, the FDA approved a 40 mg dose of 
GA injected three times per week (“Copaxone,” n.d.).  
 GA functions as an immunomodulator; however, the mechanism remains 
incompletely understood (Mallucci et al., 2015). GA treatment elicits protective anti-
inflammatory responses in dendritic cells and monocytes.  Based on a study by Vieira et 
al. (2003), GA-treated dendritic cells produced fewer TNF-α inflammatory cytokines. 
Additionally, GA exhibited an inhibitory effect on monocytes and promoted a shift from 
Th1 inflammatory cells to Th2 anti-inflammatory cells (Weber et al., 2004). Wei et al. 
(2015) illustrated that GA significantly attenuates TNF-α induced phosphorylation of 
IκBα, which inhibits its breakdown and prevents the translocation of NF-κB into the 
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nucleus and activation of NF-κB induced gene transcription. These findings suggested 
that GA functions via NF-κB inhibition and chemokine production attenuation (Wei et 
al., 2015). 
 During a 2-year placebo-controlled phase III trial, patients treated with GA 
experienced a significant reduction in mean relapse rate compared to those in the placebo 
group (Johnson et al., 1995). Although significant differences in the mean number of 
days until relapse and the proportion of relapse-free patients were not observed between 
the two treatment groups, highly favorably trends were observed for GA therapy 
(Johnson et al., 1995). More GA-treated patients showed improvement in their EDSS 
score, while patients in the placebo group were more likely to experience a progression of 
one or more points (Johnson et al., 1995).  
 The most common adverse events were localized injection site reactions, 
including itching, swelling, and erythema (Johnson et al., 1995). Palpitation, tightness 
around the chest, dyspnea, and associated anxiety occurred sporadically during or within 
minutes of an injection, generally persisted between 30 seconds and 30 minutes, and 
passed with no residual difficulties (Johnson et al., 1995). This unpredictable reaction 
was the only adverse event to occur significantly more often in the GA-treated patients 
than in the placebo-treated ones (Johnson et al., 1995). Overall, GA treatment was well 
tolerated in MS patients. 
 Both GA and IFNβ significantly reduce the relapse rate and disability 
progression. They have long been the preferred first-line therapies and, not surprisingly, 
have undergone several head to head efficacy and safety comparisons. Five trials 
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(BECOME, BEYOND, REGARD, Calabrese, and COMBIRX) directly compared IFNβ 
and GA over the course of 2 years, with the exception of the 3-year COMBIRX trial (La 
Mantia et al., 2014). A review of these randomized controlled trials concluded that, in 
relation to clinical efficacy and safety, IFNβ does not appear to differ from GA (La 
Mantia et al., 2014). However, all of these studies observed a greater benefit on MRI 
parameters of disease using in the IFNB arm. It observed a significant reduction in the 
number of enlarging T2 hyperintense lesions of IFNβ-treated patients (La Mantia et al., 
2014). 
 
Natalizumab 
A 300 mg dose of intravenous natalizumab is administered every four weeks for 
the treatment of RRMS (Mallucci et al., 2015). Natalizumab, a humanized monoclonal 
antibody, selectively inhibits the α4 subunits of α4β1 and α4β7 integrins and prevents 
their interaction with VCAM-1 and mucosal addressin-cell adhesion molecule 1, 
respectively (Polman et al., 2006). This DMT stabilizes the blood-brain barrier. The 
diapedesis of lymphocytes into the brain is facilitated by the binding of the α4β1 integrin, 
on the surface of lymphocytes, and the VCAM-1, on the surface of vascular endothelial 
cells (Polman et al., 2006). The adhesion of mononuclear cells to the endothelium 
requires α4β1 integrins (Yednock et al., 1992). According to Yednock et al., the α4β1 
integrin contains binding domains for fibronectin (FN) and VCAM-1 adhesion (Yednock 
et al., 1992). Although the FN-binding site is not involved in adhesion, FN may facilitate 
leukocyte migration across the wall of the vasculature (Yednock et al., 1992). 
	   21	  
Natalizumab has a rapid onset and has advantageous effects on relapse rate, lesion 
activity, and progression of disability in RRMS patients. Illustrated in the study by 
Polman et al. (2006), natalizumab reduced the Annualized Relapse Rate (ARR) by 68% 
after one year of treatment, which was maintained at the two-year study end point. Sixty-
seven percent of patients treated with the intravenous drug were relapse free at two years, 
which was significantly greater than the 41% of patients in the placebo group (Polman et 
al., 2006). The monoclonal antibody diminished the risk of disability progression by 42% 
to 54% (Polman et al., 2006). In comparison to the placebo, natalizumab significantly 
decreased the amount of new or enlarging T2-hyperintense lesions and the amount of 
Gd+ lesions over two years (Polman et al., 2006).  
Polman outlines the frequencies of adverse events. Occurring in 10% or more of 
the patients, headache, fatigue, arthralgia, depression, infection, and allergic reaction 
were the most common adverse events (Polman et al., 2006). Fatigue and allergic 
reaction occurred with significant frequency in patients treated with natalizumab versus 
the placebo. However, the rate of infection between the natalizumab and placebo groups 
was insignificant, with infection occurring 1.52 and 1.42 per patient-year, respectively 
and serious infections occurring in 3.2% and 2.6% of patients (Polman et al., 2006). 
Relapse and cholelithiasis were the most common serious adverse events. Similar 
proportions of patients in both the natalizumab and placebo groups discontinued the study 
due to adverse events (Polman et al., 2006).  
Observed in a study by Bloomgren et al. (2012), progressive multifocal 
leukoencephalopathy (PML) is associated with use of natalizumab in the presence of 
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several risk factors. Caused by the John Cunningham (JC) virus, PML is an infection of 
the brain that attacks the oligodendrocytes resulting in severe disability and death 
(Bloomgren et al., 2012). Positive anti-JC virus status, prior use of immunosuppressants, 
and increased duration of natalizumab treatment correlated with an increased prevalence 
of PML (Bloomgren et al., 2012). It was estimated that the incidence of PML in patients 
with a positive anti-JC virus status was greater by a factor of forty-fold than patients 
negative for anti-JC virus antibodies (Bloomgren et al., 2012). Patients with a negative 
anti-body status incur essentially no risk; however, viral statuses may change throughout 
the course of treatment. PML risk increases with increasing treatment duration, with the 
greatest risk occurring in populations on natalizumab therapy over 2 years (Bloomgren et 
al., 2012). While any of these three factors incur a significant risk, patients with a 
combination of all risk factors have the highest estimated occurrence of PML (Bloomgren 
et al., 2012).  
With 50-60% of the average population testing positive for anti-JC virus 
antibodies and infection increasing with age, natalizumab use in RRMS patients should 
be monitored closely (Sedal et al., 2014). According to Sedal et al. (2014), current 
practices indicate MRI scanning of anti-JC virus antibody positive patients every 4 
months and negative patients every 6 to 12 months with biannual clinical status checks. 
Additionally, leukocyte levels should be within the normal range prior to starting 
treatment. The presence or absence of anti-JC virus antibodies, prior usage of 
immunosuppressive therapies, and the severity of the patient’s MS should be taken into 
consideration while determining the suitability of natalizumab therapy (Bloomgren et al., 
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2012). If viable candidates, patients with positive antibody statuses treated with 
natalizumab for longer than two years may want to consider other treatment options 
 
Fingolimod 
Taken orally, fingolimod was the first MS DMT of its kind. A 0.5 mg dose is 
administered daily (Mallucci et al., 2015). Fingolimod inhibits the egress of lymphocytes 
from lymph nodes, rending them unavailable to initiate an inflammatory event (Kappos et 
al., 2010). Fingolimod accomplishes this through sphingosine-1-phosphate (SIP) pathway 
potentiation (Kappos et al., 2010). According to the FREEDOMS study, fingolimod 
significantly reduced the ARR 54% at a dose of 0.5 mg at the two-year study end when 
compared with the placebo (Kappos et al., 2010). Witnessed as early as three months post 
treatment initiation, both trial doses of fingolimod lessened the risk of disability 
progression over the course of the study (Kappos et al., 2010). Patients treated with 
fingolimod had significantly fewer Gd+ lesions, fewer new or enlarging T2 hyperintense 
lesions, and a reduction in T2 hyperintense lesion volume (Kappos et al., 2010). 
The proportion of patients that experienced adverse events was comparable across 
the study groups. The most common adverse events, occurring 10% or more of patients, 
included infection, headache, abnormal liver function, fatigue, and back pain (Kappos et 
al., 2010). Abnormally low levels of white blood cells were observed in patients taking 
fingolimod, which may lead in an increase in the incidence of infection (Kappos et al., 
2010). Seen in the FREEDOMS extension trial, the resurgence of latent herpes virus 
infections was of special interest (Kappos et al., 2015).  Bradycardia, MS relapse, 
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macular edema, and basal cell carcinoma were the most common serious adverse events, 
occurring in less than 1% of patients (Kappos et al., 2010). According to the 
FREEDOMS extension trial, the cardiovascular episodes were generally observed within 
six hours of the administration of the first dose, but resolved and did not recur (Kappos et 
al., 2015). 
Numerous important contraindications require specific laboratory tests and 
assessments prior to treatment initiation. A patient’s personal and familial history of 
cardiovascular disease should be taken into consideration prior to treatment with 
fingolimod. Patients with a heart block or taking drugs that alter atrioventricular 
conduction should receive special attention. Fingolimod requires cardiac monitoring via 
electrocardiography following the administration of the first dose (Sedal et al., 2014). 
Leukocyte counts should be measured prior and monitored throughout treatment 
duration. Additionally, it is advisable to test for herpes zoster antibodies, and if the 
patient has a negative status, vaccination is recommended (Sedal et al., 2014). Liver 
function should be regularly tested, and patients with hepatic or renal impairment may 
require dose adjustments. Ophthalmologic and dermatologic evaluations are 
recommended post initiation of fingolimod therapy (Sedal et al., 2014). 
The TRANSFORMS study compared the usage of oral fingolimod with 
intramuscular IFNβ-1a for the treatment of RRMS (Khatri et al., 2011). In the core study, 
patients were randomly assigned to one of three groups: 0.5 mg daily fingolimod, 1.25 
daily oral fingolimod, or 30 µg weekly intramuscular IFNβ-1a (Khatri et al., 2011). In the 
13-24 month extension, patients in the IFNβ-1a group were reassigned to either 
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fingolimod group, and the patients initially treated with fingolimod continued with their 
treatment protocol (Khatri et al., 2011). Patients who switched to fingolimod from IFNβ-
1a had reductions in ARR of 30% on a 0.5 mg daily dose (Khatri et al., 2011). 
Significantly fewer patients had relapses post switch than during the 12 months of IFNβ-
1a treatment (Khatri et al., 2011). Switching to either fingolimod group resulted in 
significant reductions in the number of new or enlarging T2 hyperintense lesions (Khatri 
et al., 2011). Additionally, more patients were free from new or enlarging T2 
hyperintense lesions (Khatri et al., 2011). The number of new or enlarging Gd+ lesions 
was reduced during the year following the switch to fingolimod (Khatri et al., 2011).  
Throughout months 13-24, the beneficial clinical and MRI measures of disease 
were maintained or improved in patients on continuous fingolimod therapy (Khatri et al., 
2011). During the 2-year study course, ARR was significantly reduced by 46% in 0.5 mg 
fingolimod group compared with either IFNβ-1a to fingolimod switch group (Khatri et 
al., 2011). More patients in the continuous 0.5 mg fingolimod group were free from new 
T2 lesions and had significantly fewer new or enlarging T2 lesions compared to the 
switch group (Khatri et al., 2011). In comparison to the switch group, continuous 
fingolimod treatment resulted in significantly fewer Gd+ lesions over 24 months and a 
greater proportion of patients free from Gd+ lesions (Khatri et al., 2011). No significant 
difference between either continuous fingolimod groups or the switch group was 
observed in the EDSS score (Khatri et al., 2011).  
Considered more efficacious than injectable DMTs, natalizumab and fingolimod 
are commonly used as second-line therapies for the treatment of RRMS in the event of 
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treatment failure or intolerability (Kalincik et al., 2015). A prospective cohort study 
performed by Kalincik et al. (2015) compared the efficacy of switching to natalizumab or 
fingolimod as a result of injectable DMT treatment failure. Both treatment groups 
experienced decrease in ARR (Kalincik et al., 2015). The relapse rate was 50% lower for 
patients who switched to natalizumab than fingolimod (Kalincik et al., 2015). 
Congruently, a greater proportion of patients on natalizumab were relapse free at the 
study’s end (Kalincik et al., 2015). No significant difference between the treatment 
groups was observed in the 6-month sustained disability rates (Kalincik et al., 2015). 
However the likelihood of experiencing a 6-month sustained regression of disability was 
2.8 times greater for patients treated with natalizumab (Kalincik et al., 2015). Based on 
this study, switching from injectable DMTs to natalizumab was more effective in 
reducing the rate of relapse and short-term disability in active RRMS (Kalincik et al., 
2015). 
 
Dimethyl fumarate 
Two hundred forty milligrams of dimethyl fumarate (DMF) is administered orally 
twice daily (Mallucci et al., 2015). Fumaric acid esters modulate the immune response 
through the production of anti-inflammatory Th2 cytokines (Mrowietz et al., 1998). 
Beyond its immunomodulatory properties, DMF is believed to have neuroprotective 
properties.  
Based on a study performed by Scannevin et al. (2012), DMF and monomethyl 
fumarate (MMF), a DMF metabolite, induced the nuclear factor erythroid-derived 2-like 
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2 (Nrf2) antioxidant response pathway in CNS cells. This study suggested that astrocytes, 
oligodendrocyte progenitor cells (OPCs), and possibly neurons respond to DMF and 
MMF, inducing the cytoprotective response (Scannevin et al., 2012). MMF increased 
intracellular levels of glutathione (GSH), an important antioxidant that prevents damage 
to cellular components caused by reactive oxygen species (ROS) (Scannevin et al., 2012).  
According to the DEFINE and CONFIRM studies, delayed-release DMF 
significantly reduced new or enlarging T2 hyperintense and Gd+ lesions compared with 
placebo at the two-year study end (Douglas et al., 2014; Fox et al., 2012). Reductions in 
the number and volume of both lesion types, as well as the number of T1 hypointense 
lesions were observed at six months and sustained throughout the trial period (Douglas et 
al., 2014). Reduction in the volume of T1 hypointense lesions was first observed at one 
year from the onset of treatment (Douglas et al., 2014).  
A significant reduction in the number of patients who experienced at least one 
relapse in the two-year study period was observed for DMF b.i.d. administration (Gold et 
al., 2012). Treatment with DMF b.i.d. resulted in a 49% reduction in the risk of relapse 
(Gold et al., 2012). The ARR at two years was reduced 53% patients treated with DMF 
b.i.d. (Gold et al., 2012). Compared to 27% of patients taking the placebo, 16% of 
patients treated with DMF b.i.d. experienced a progression of disability (Gold et al., 
2012).  
 Adverse events, ranging from mild to moderate severity, occurred across all three 
groups, but with greater frequency in groups receiving DMF (Gold et al., 2012). Most of 
the adverse events were mild and reversible and did not result in the discontinuation of 
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treatment. The most frequently reported adverse events included flushing, relapse, 
diarrhea, nausea, upper abdominal pain, proteinuria, abdominal pain, pruritus, and 
vomiting (Gold et al., 2012). Flushing and gastrointestinal events occurred most 
frequently in the first month, tapering off thereafter (Gold et al., 2012). With the 
exception of relapse, serious adverse events occurred less than 1% of the time (Gold et 
al., 2012; Fox et al., 2012). In DMF treatment groups, white-cell counts and lymphocytes 
decreased by approximately 10% within one year, but then plateaued within normal 
ranges (Gold et al., 2012). Only 4% of patients had white-cell counts less than 3.0 x 10^9 
per liter and lymphocyte counts less than 0.5 x 10^9 per liter (Gold et al., 2012). 
 
Teriflunomide 
Approved by the FDA in 2012 for RRMS, oral teriflunomide, an active metabolite 
of leflunomide, is administered daily at either a dose of 7 or 14 mg (Mallucci et al., 
2015). Although its mechanism is not fully elucidated, teriflunomide inhibits 
mitochondrial dihydroorotate dehydrogenase, which is critical in the de novo synthesis of 
pyrimidines (Claussen and Korn, 2012). Pyrimidine synthesis inhibition and pyrimidine 
pool depletion effectively suppresses lymphocyte function (Claussen and Korn, 2012). 
Additionally, teriflunomide inhibits the interaction between APCs and T cells (Claussen 
and Korn, 2012). Teriflunomide targets rapidly proliferating immune cells, while 
preserving the function of slowly dividing cells that utilize exogenous pyrimidine 
supplies (Claussen and Korn, 2012). 
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 Based on a 108-week study conducted by O’Connor et al. (2011), oral 
teriflunomide significantly reduced the risk of relapse in comparison with placebo by 
31.2% and 31.5% with 7 mg and 14 mg, respectively. Additionally, the TOWER trial 
confirmed a significant beneficial effect of 7 and 14 mg teriflunomide on the ARR 
(Confavreux et al., 2014). Both dosages extended the time to the first relapse and 
increased the number of relapse free patients (O’Connor et al., 2011). The 12 week 
sustained disability progression did not differ significantly between the placebo group 
and the teriflunomide groups (O’Connor et al., 2011). Several MRI measures of disease 
activity were significantly improved by teriflunomide (O’Connor et al., 2011). 
Significant reductions in T2 hyperintense lesion volume from the baseline were observed 
for 14 mg teriflunomide (O’Connor et al., 2011). Patients in both active treatment groups 
had significantly fewer Gd+ lesions (O’Connor et al., 2011). Alterations in brain atrophy 
were not significantly different among teriflunomide groups and placebo group 
(O’Connor et al., 2011).  
 Similar proportions of adverse events occurred among the three study groups 
(O’Connor et al., 2011). Occurring in greater than or equal to 10% of teriflunomide 
patients, nasopharyngitis, headache, diarrhea, fatigue, elevated alanine aminotransferase 
levels, hair thinning, influenza, and pain in arms, legs or back were the most common 
adverse events (O’Connor et al., 2011). Additionally, pregnancy was treated as an 
adverse event, since the therapy has not been approved for this population (O’Connor et 
al., 2011). Two cases of PML were observed during long-term exposure of leflunomide 
for the treatment of rheumatoid arthritis (O’Connor et al., 2011).  
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 In a head to head study, no significant difference in ARR existed between 14 mg 
teriflunomide and IFNβ-1a; however, ARR was significantly higher in patients treated 
with 7 mg teriflunomide (Vermersch et al., 2013). Similar effects on time to failure were 
observed among the three study groups (Vermersch et al., 2013). It can be concluded that 
teriflunomide at the higher dose of 14mg/day has an efficacy similar to that of self-
injectable DMTs and is appropriate for utilization as a first line therapy. Although FDA 
approved, the 7 mg teriflunomide is rarely utilized in clinical practice. 
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III. Regenerative Therapeutics 
 
Immune modulation has been the primary focus of MS medications for the past 
20 years. These medications reliably stave off relapse and long-term disability that occurs 
as a result of relapses but have not been proven beneficial for patients with progressive 
MS. The clinical benefit of these drugs is undeniable; however this benefit is primarily 
limited to RRMS. Emerging therapies aim to reverse neurodegenerative damage via OPC 
stimulation. Remyelinating therapies appear promising for the treatment of all stages of 
MS. 
 Stimulation of OPC migration and differentiation is directed by regulatory signals 
(Bradl and Lassmann, 2009). Certain growth factors, chemotropic molecules, and 
chemokines, as well as contact-mediated mechanisms, play a role in OPC migration 
(Bradl and Lassmann, 2009). Differentiation is spatially and temporally regulated through 
signaling processes such as Notch1, leucine-rich repeat and immunoglobin domain-
containing Nogo receptor-interacting protein (LINGO-1), and γ-secretase and other 
unidentified molecular mechanisms (Bradl and Lassmann, 2009). Highly coordinated, 
ensheathment of axons occurs during a 12 to 18 hour window early on in OPC 
differentiation (Bradl and Lassmann, 2009). Oligodendrocytes produce and support 
membranes, comprise mainly of myelin basic protein (MBP) and proteolipid protein 
(PLP), as large as 100 times its cell body weight (Bradl and Lassmann, 2009).  
In order to produce these necessary proteins, myelinating oligodendrocytes have 
tremendous metabolic rates and therefore consume large quantities of oxygen and ATP 
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(Bradl and Lassmann, 2009). Hydrogen peroxide and reactive oxygen species are toxic 
byproducts of this rapid metabolism (Bradl and Lassmann, 2009). Furthermore, 
myelination requires iron, which under unfavorable conditions promotes the production 
of peroxides and radical species (Bradl and Lassmann, 2009). A decrease in the fidelity 
of protein synthesis, a rapid metabolic rate, and high intracellular iron concentrations 
render oligodendrocytes particularly vulnerable to oxidative damage and mitochondrial 
injury (Bradl and Lassmann, 2009).  
 Additional, inflammatory cytokines may cause oligodendrocyte damage or death 
(Bradl and Lassmann, 2009). TNF-α can stimulate oligodendrocyte apoptosis, while IFNγ 
is highly toxic for proliferating OPCs and slightly toxic for immature oligodendrocytes 
(Bradl and Lassmann, 2009).  
 These mechanisms are promising targets for pharmaceutical development. 
Numerous compounds are in various stages of clinical development and may prove 
efficacious for all MS phenotypes. Additionally various approved MS therapies are under 
investigation for possible regenerative and neuroprotective properties. Below, four 
therapeutics with reparative potential which are currently being studied, are discussed.  
 
Monoclonal antibody BIIB033 
LINGO-1, a transmembrane protein expressed in neurons and OPCs, negatively 
regulates neurite outgrowth and oligodendrocyte differentiation and myelination via the 
RhoA pathway (Mi et al., 2005). RhoA-GTP mediates actin polymerization and 
cytoskeleton configuration, and LINGO-1 decreases intracellular levels (Mi et al., 2005). 
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Inhibition of LINGO-1 promoted myelination and greatly reduced disease severity at all 
stages in EAE animal models (Tran et al., 2014). Monoclonal antibody BIIB033 binds 
LINGO-1 with high affinity and specificity (Tran et al., 2014). BIIB033 has a limited 
ability to cross the blood-brain barrier, but the systemic delivery of high doses has proved 
efficacious (Tran et al., 2014). In phase I clinical trials, doses up to 100 mg/kg were well 
tolerated, with headache, upper respiratory and urinary tract infection, nasopharyngitis, 
and gastroenteritis among the most common adverse events (Tran et al., 2014). No 
serious adverse events or deaths occurred (Tran et al., 2014). Additionally, only two 
participants in BIIB033 groups tested positive anti-BIIB033 antibodies, suggesting a low 
immunogenicity (Tran et al., 2014). BIIB033 is currently in phase 2 trials (Kremer et al., 
2015). 
 
rHIgM22  
Fibroblast growth factor (FGF-2) produced by neuronal cells, astrocytes, and 
microglia, upregulates platelet-derived growth factor (PDGF) alpha receptor expression 
on early OPCs (Watzlawik et al., 2013). In conjunction with their receptors, neuronal 
cells and astrocytes produce PDGF, a potent mitogen, which stimulates early OPC 
proliferation and promotes survival in OPCs (Watzlawik et al., 2013). More mature cells 
in the oligodendrocyte lineage are not mediated by PDGF (Watzlawik et al., 2013). This 
PDGF pathway is considered a possible target for the human monoclonal IgM antibody, 
rHIgM22. 
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According to several animal models, rHIgM22 accumulates in lesions and 
indirectly promotes OPC proliferation and myelination in the presence of PDGF and 
inhibits apoptotic signaling in OPCs (Warrington et al., 2007; Watzlawik et al., 2013). 
The monoclonal antibody may increase the sensitivity of OPCs to endogenous repair 
factors (Watzlawik et al., 2013). These favorable preclinical studies have prompted an 
investigative phase I clinical trial for use of intravenous rHIgM22 in MS patients 
(Kremer et al., 2015). 
 
GNbAC1 
Human endogenous retrovirus type W (HERV-W) occupies up to 8% of the 
human genome (Kremer et al., 2013). The reactivation of HERV-W may secrete 
extracellular viral particles that exert a proinflammatory event (Kremer et al., 2013). 
These particles are strongly associated with clinical disease progression and prognosis 
(Kremer et al., 2013). According to a study performed by Kremer et al. (2013), the 
envelope protein (ENV) of HERV-W inhibited the endogenous repair capacity of the 
CNS. ENV-mediated activation of OPC expressed toll-like receptor 4 (TLR4) and 
stimulated the production of proinflammatory cytokines, iNOS, and nitrotyrosine groups, 
which consequently inhibited OPC differentiation (Kremer et al., 2013).  
 GNbAC1 is a humanized monoclonal anti-ENV antibody (Kremer et al., 2014). It 
reduces the ENV-mediated proinflammatory cytokine transcription, nitrotyrosine 
formation, and iNOS induction, making it a promising candidate for a two-pronged 
therapeutic approach (Kremer et al., 2014). In phase IIa randomized placebo-controlled 
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clinical study, eight patients received five infusions, one every four weeks, of either 2 or 
6 mg/kg intravenous dose of GNbAC1 (Derfuss et al., 2014). GNbAC1 was well 
tolerated, and the incidence of adverse events did not differ between the two study groups 
(Derfuss et al., 2014). One serious adverse event was reported, but it was considered to 
be unrelated to the treatment (Derfuss et al., 2014). Throughout the entire study period, 
no patient developed antibodies against GNbAC1, suggesting low immunogenicity 
(Derfuss et al., 2014). With one exception, patients had stable MRI measures of disease 
progression at six months (Derfuss et al., 2014). This study observed no changes in 
cytokine profiles, but it can be assumed that changes would only be observed with a 
longer treatment period (Derfuss et al., 2014). Further investigations into the safety and 
efficacy of GNbAC1 are schedule to start in 2015 (Kremer et al., 2015).  
 
Benztropine 
Benztropine is an orally available FDA approved drug that readily crosses the 
blood-brain barrier and is employed for the management of Parkinson’s disease and 
dystonia (Deshmukh et al., 2013). It is a centrally acting anti-histamine, a dopamine re-
uptake inhibitor, and a cholinergic receptor inhibitor; the latter is believed to produce the 
primary pharmacological effects (Deshmukh et al., 2013). A study performed by 
Deshmukh et al. (2013) explored the potential therapeutic effects of benztropine for the 
treatment of MS. 
Benztropine induced differentiation of immature OPCs and remyelination in EAE 
rodent models (Deshmukh et al., 2013). Benztropine-induced differentiation was 
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inhibited in the presence of carbachol, suggesting that its mechanism of action is 
dependent on M1/M3 muscarinic receptor antagonism (Deshmukh et al., 2013). 
Furthermore, other muscarinic acetylcholine receptor antagonists induced OPC 
differentiation, but benztropine was the most potent of the tested compounds 
(Ddeshmukh et al., 2013). In this study, daily intraperitoneal injection led to functional 
recovery, significantly decreased clinical severity comparable to or better than 
fingolimod or IFNβ, and essentially eliminated the risk of relapse (Deshmukh et al., 
2013). Benztropine did not influence leukocyte infiltration, prevalence, or activity 
(Deshmukh et al., 2013). Additionally, the combination of suboptimal doses of 
benztropine and fingolimod was assessed, with favorable outcomes. Clinical severity was 
significantly decreased, and benztropine had no adverse effect on the immunomodulatory 
capacity of fingolimod and visa versa (Deshmukh et al., 2013). 
 Further preclinical and clinical evaluation of benztropine will be required prior to 
its use in MS patients. This avenue should be further explored. 
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IV. Treatment Plans  In	  the	  early	  to	  mid	  90s,	  the	  FDA	  approved	  the	  first	  MS	  disease	  modifying	  therapy,	  interferon	  beta.	  Since	  then	  several	  immunomodulatory	  and	  immunosuppressant	  drugs	  have	  been	  approved.	  No	  cure	  exists	  for	  MS.	  These	  drugs	  can	  partially	  ameliorate	  and	  delay	  clinical	  and	  MRI	  measures	  of	  disease	  progression,	  but	  they	  are	  associated	  with	  adverse	  effects	  and	  risks.	  Along	  with	  these	  contraindications,	  the	  heterogeneous	  nature	  of	  the	  disease	  may	  obfuscate	  one’s	  ability	  to	  select	  the	  most	  suitable	  therapy.	  
Although subcutaneous and intramuscular injectable DMTs have been widely 
prescribed for the past two decades, the introduction of intravenous and oral therapies 
have provided patients with a variety of treatment options. IFNβ and GA have well 
documented safety profiles with minimal side effects and are increasingly utilized as 
first-line therapies. RRMS patients generally respond well, and with minimal adverse 
effects, to the first-generation self-injectable DMTs. Nevertheless, injectable therapies 
have notoriously low adherence and persistence rates in comparison to other available 
MS treatments (Wingerchuk and Carter, 2014). While it seems prudent to utilize a time-
proven therapy, medications are only effective if taken properly. Furthermore, clinical 
efficacy and the consequences of chronic inflammation on the CNS should be taken into 
consideration when devising a treatment plan.  
Oral medications provide a convenience that the other MS medications lack. They 
are easily administered and do not require special handling or training. Three oral 
	   38	  
medications, ranging in safety and efficacy, have been approved for the treatment of 
RRMS: teriflunomide, DMF, and fingolimod.  
Once-daily oral teriflunomide, although an effective therapy, does not 
demonstrate a significant difference compared to IFNβ-1a therapy. Special monitoring is 
required for its administration due to the risk of hepatotoxicity and a long half-life. 
Additionally, teriflunomide has not been approved for the use in pregnancy. In the event 
of overdose, treatment discontinuation, pregnancy, or the desire to become pregnant, 
teriflunomide’s elimination can be increased with the administration of cholestyramine 
(O’Connor et al., 2011). With a predominately younger female population, adverse 
events such as hair loss and potentially teratogenic effects are major deterrents. This 
medication is perhaps more suitable for patients with intolerances to other medications 
and those beyond child bearing years. Furthermore, while no direct comparisons have 
been made, it does not appear that teriflunomide has superior efficacy over the other 
available MS therapies. 
The DEFINE and CONFIRM phase 3 studies illustrated the beneficial effects of 
twice-daily oral DMF as an immunomodulatory therapy for RRMS. The CONFIRM trial, 
though not a direct comparison, evaluated the benefit of DMF versus GA and estimated 
that DMF had similar or greater efficacy to GA across treatment end points (Fox et al., 
2012). Treatment with DMF resulted in a greater reduction in ARR (Fox et al., 2012). As 
well as being an immunomodulatory, DMF is believed to have neuroprotective 
properties. 
	   39	  
Once-daily oral fingolimod has been approved as a first-line therapy for RRMS, 
but it is often reserved as a second-line therapy. It arguably requires the most intensive 
laboratory and physical assessments upon treatment initiation. The FREEDOMS and 
TRANSFORMS trials illustrated the superior efficacy fingolimod compared with IFNβ-
1a. As made evident by the prospective cohort study performed by Kalincik et al. (2014), 
natalizumab has greater beneficial effects on ARR, sustained disability regression, and 
MRI measures of disease activity, yet natalizumab’s associated PML risk is a reasonable 
deterrent.  
Although lacking direct comparisons, natalizumab is generally considered the 
most efficacious RRMS therapy available. It is also the most invasive therapy, since it 
may only be administered intravenously. Regardless of its superior efficacy, natalizumab 
is associated with an increased risk of developing PML correlating to a prior or new 
infection with the JC virus. Viral statuses, of patients that start natalizumab therapy with 
a negative JC virus status, should be check regularly. Furthermore, the wholesale cost of 
the medication is very expensive, and there are additional costs for infusions and 
monitoring. This medication is perhaps best suited as a second-line therapy for patients 
that have experienced treatment failure and disability progression. 
Choosing the appropriate therapy is highly complex, with a variety of contributing 
factors. Medical history, disease aggressiveness, tolerance, adherence, financial burden, 
quality of life, and lifestyle should all be taken into consideration before treatment 
application. Treatment strategies may include the utilization of MS drugs in a sequential 
manner (Figure	  4).	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Figure 4. Sequential Therapeutic Strategy for MS.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Fingolimod is approved as a first line therapy but is generally reserved as a second line 
therapy. 
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Given	  that	  MS	  is	  the	  most	  prevalent	  disabling	  neurological	  condition	  among	  young	  adults,	  hundreds	  of	  millions	  of	  dollars	  are	  dedicated	  for	  the	  research	  and	  development	  of	  new	  and	  improved	  pharmaceuticals.	  Remarkable	  progress	  and	  innovations	  in	  MS	  therapy	  have	  been	  seen	  in	  the	  past	  two	  decades.	  Preventing	  disease	  progression	  and	  improving	  from	  acquired	  deficits	  should	  be	  the	  objective	  of	  future	  therapeutics.	  With little available for patients suffering from progressive forms of 
MS, this future research should be directed toward filling this treatment gap.  
Emerging remyelinating therapies have yielded promising results in animal 
models for the treatment of all stages of MS. These drugs could likely be utilized in 
conjunction with immunosuppressive therapies. Humanized	  anti-­‐monoclonal	  antibodies	  have	  elicited	  high	  levels	  of	  research	  interest.	  Additionally,	  antihistamine	  and	  anticholinergic	  compounds	  have	  been	  identified	  as	  promoters	  of	  OPC	  differentiation	  (Kremer	  et	  al.,	  2015). Aside from novel remyelinating therapies, 
available pharmaceuticals are being reassessed for additional regenerative properties and 
repurposed.  Personalized	  DMT	  strategies	  are	  on	  the	  pharmaceutical	  horizon	  for	  the	  treatment	  of	  multiple	  sclerosis.	  Scientists	  are	  making	  breakthroughs	  in	  identifying	  risk	  factors,	  and	  with	  the	  advancements	  in	  genomics,	  answers	  regarding	  the	  etiology	  of	  MS	  may	  soon	  be	  tangible.	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